What We're Reading: Page 249
Industry reads hand-picked by our editors
Oct 19, 2018
Oct 18, 2018
-
MIT Technology Review
We can now customize cancer treatments, tumor by tumor
-
Bloomberg
An ETF banking on the next big drug breakthrough
-
The Washington Post
Big Pharma is hurting drug innovation
-
Associated Press
Rising drug prices widen gap between have, have-not patients
Oct 17, 2018
Oct 16, 2018
-
FiercePharma
Got tech ideas for diabetes? Novo wants you for its crowdsourcing challenge
-
The Atlantic
Neanderthals suffered a lot of traumatic injuries. So how did they live so long?
-
The New York Times
Most white Americans' DNA can be identified through genealogy databases
-
Stat
Harvard and the Brigham call for more than 30 retractions of cardiac stem cell research
Oct 15, 2018
-
BBC
Why gene editing could create so many jobs
-
The New York Times
Tiny nanoparticles to treat a huge problem: Snakebites
-
The Wall Street Journal
Chinese drugmaker’s IPO tests a slumping biotech market
Oct 12, 2018
-
Bloomberg
Bayer weighs selling its vet unit in post-Monsanto revamp
-
Fortune
Why cancer biotech Allogene just scored an eye popping $324 million IPO
-
Wired
Antibiotics may soon become useless. Now what?
-
San Francisco Business Times
Tech and biotech on collision course, squeezed by the Peninsula's limited space
-
The Atlantic
Photographing the microscopic: Winners of Nikon Small World 2018
Oct 11, 2018
-
The Wall Street Journal
Biotech is down but far from out
-
Politico
Get ready for a Rx drug-supplement war
-
Xconomy
In New York, Gotham starts up with $54M for RNA-modifying drugs
-
The Washington Post
Republicans and Democrats paint scary visions for health care if the other side wins
Previous
